Skip to main content

Table 1 Patients Characteristics

From: A randomized phase III study of the docetaxel/carboplatin combination versus docetaxel single-agent as second line treatment for patients with advanced/metastatic Non-Small Cell Lung Cancer

 

DC

(n = 67)

D

(n = 65)

 
 

N (%)

N (%)

P-value

Age

62

63

 

Median (min-max)

39 - 78

39 - 83

 

Sex

   

Male

64 (95.5)

56 (86.2)

P = 0.074

Female

3 (4.5)

9 (13.8)

 

Performance status

   

0

26 (38.8)

14 (21.5)

P = 0.088

1

33 (49.3)

39 (60.0)

 

2

8 (11.9)

12 (18.5)

 

Histological Type

   

Squamous

16 (23.9)

18 (27.7)

Adeno Ca vs Non-Adeno Ca

P = 0.380

Adeno Ca

26 (38.8)

31 (47.7)

 

Large Cell

2 (3.0)

1 (1.5)

 

Mixed

1 (1.5)

1 (1.5)

 

Other

22 (32.8)

14 (21.5)

 

No. of Organs Involved

   

Median (min- max)

2.00 (1 - 8)

2.00 (1 - 5)

1-2 vs > = 3

P = 0.444

   

Mann-Whitney U = 2142.500

P = 0.867

Prior therapy

   

Paclitaxel

8 (11.9)

7 (10.8)

P = 0.109

Response to prior therapy

  

CR+PR vs SD+PD

P = 0.799

CR

1 (1.5)

1 (1.5)

 

PR

7 (10.4)

8 (12.3)

 

SD

18 (26.9)

19 (29.2)

 

PD

41 (61.2)

37 (56.9)

 
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us